(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices) |
(Zip Code) |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 2 40.1 4d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class |
Trading Symbol(s) |
Na me of each exchangeon which registered | ||
* |
* | The registrant’s common stock began trading on the OTC Pink Marketplace on April 3, 2023 under the symbol “CALC.” |
Item 9.01 |
Financial Statements and Exhibits |
Exhibit No. |
Description | |
23.1 | Consent of Independent Registered Public Accounting Firm. | |
99.1 | Audited Financial Statements of CalciMedica, Inc. for the years ended December 31, 2022 and 2021. | |
99.2 | Unaudited Pro Forma Combined Financial Statements. | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
Date: April 4, 2023 | CalciMedica, Inc. | |||||
By: | /s/ A. Rachel Leheny, Ph.D. | |||||
Name: | A. Rachel Leheny, Ph.D. | |||||
Title: | Chief Executive Officer |